124I-MIBG剂量学指导的高活度131I-MIBG治疗晚期嗜铬细胞瘤或神经母细胞瘤的疗效与安全性
本研究纳入14例晚期嗜铬细胞瘤或神经母细胞瘤患者(年龄9-69岁),采用124I-MIBG PET扫描和全身滞留测量评估全身剂量和肿瘤吸收剂量,指导单次高活度131I-MIBG治疗。平均治疗活度为14 GBq,中位总生存期85个月,中位无进展生存期25个月,RECIST和功能影像的缓解率分别为29%和36%,不良事件多为可管理的低级别毒性。
要点
- 124I-MIBG剂量学指导的单次高活度131I-MIBG治疗在晚期嗜铬细胞瘤或神经母细胞瘤中产生持久缓解。
- 14例中11例(79%)接受超过10 GBq的治疗活度,1例男性接受单次50 GBq。
- 1例超过全身剂量2 Gy并出现3级血液学毒性,12个月内自行缓解无需进一步治疗。
核心结论
- 124I-MIBG剂量学指导的高活度131I-MIBG治疗在晚期嗜铬细胞瘤或神经母细胞瘤患者中产生持久缓解,不良事件发生率低且可管理。
- 作者认为124I-MIBG指导的活度递增疗效应在前瞻性研究中进一步评估。
研究设计与样本
- 研究纳入14例晚期嗜铬细胞瘤或神经母细胞瘤患者,年龄9-69岁。
- 患者接受124I-MIBG PET扫描和全身滞留测量,评估全身剂量作为骨髓毒性替代指标及单位给药活度的肿瘤吸收剂量。
- 剂量学结果结合患者个体特征指导单次治疗活度,以达到高肿瘤剂量而不超过毒性阈值。
- 毒性评估包括血液学、肝功能和肾功能。
- 疗效评估采用RECIST、国际儿科肿瘤学会欧洲神经母细胞瘤样评分、PET摄取变化、定量PET参数(SUVmax、SUVpeak、代谢肿瘤体积、总病灶糖酵解)以及基线与随访124I-MIBG PET/CT上病灶数量或视觉强度的视觉减少。
主要发现
- 平均治疗活度为14 GBq;14例中11例(79%)接受超过10 GBq,1例男性接受单次50 GBq,3例接受3.5至7.0 GBq之间的较低活度。
- 中位总生存期为85个月(95% CI),中位无进展生存期为25个月(95% CI)。
- RECIST评估4例(29%)和功能影像评估5例(36%)患者达到缓解(完全缓解或部分缓解)。
- 1例患者超过全身剂量2 Gy并出现3级血液学毒性,治疗后12个月内自行缓解,无需进一步治疗。
- 3例患者(21%)出现短暂性1级肾毒性。
局限性
- 作者认为124I-MIBG指导的活度递增疗效应在前瞻性研究中进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aim to evaluate the efficacy and safety of 124I-metaiodobenzylguanidine (MIBG) dosimetry-guided high-activity 131I-MIBG therapy of advanced pheochromocytoma or neuroblastoma. Methods: Fourteen patients with advanced pheochromocytoma or neuroblastoma, age 9-69 y, underwent 124I-MIBG PET scans and whole-body retention measurements to assess the whole-body dose as a surrogate of bone marrow toxicity and tumor (absorbed) dose per unit of administered activity. Dosimetry results together with individual patient characteristics were combined to guide a single therapeutic activity to achieve a high tumor dose without exceeding toxicity threshold. Toxicity was assessed for hematologic, hepatic, and renal function. Response was evaluated by RECIST, International Society of Pediatric Oncology Europe Neuroblastoma-like score, change in PET uptake, and quantitative PET parameters (SUVmax, SUVpeak, metabolic tumor volume, total lesion glycolysis), as well as visual decrease in number or in visual intensity of lesions on baseline to follow-up 124I-MIBG PET/CT. Results: The average therapeutic activity was 14 GBq. Eleven of 14 patients (79%) received each more than 10 GBq. One male patient was treated with a single activity of 50 GBq. Three patients were treated with lower activities between 3.5 and 7.0 GBq. Median overall survival was 85 mo (95% CI), and median progression-free survival was 25 mo (95% CI). Four (29%) and 5 (36%) patients demonstrated response (complete response or partial response) by RECIST and functional imaging, respectively. One patient exceeded whole-body dose of 2 Gy and demonstrated grade 3 hematologic toxicity, which resolved spontaneously within 12 mo after the therapy without the need for further treatment. Three patients (21%) demonstrated transient grade 1 renal toxicity. Conclusion: 124I-MIBG dosimetry-guided high-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or neuroblastoma resulted in durable responses with a low rate of manageable adverse events. Efficacy of 124I-MIBG-guided activity escalation should further be assessed in a prospective setting.
引用
- Maric I, Weber M, Prochnow A, et al. Efficacy and Safety of 124I-MIBG Dosimetry-Guided High-Activity 131I-MIBG Therapy of Advanced Pheochromocytoma or Neuroblastoma. J Nucl Med. 2023. PMID: 36732054. doi:10.2967/jnumed.122.264775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。